Using an orthotopic intracerebral model from our established HM55-BGIV-101
tumor line, we investigated the antitumor effect on the angiogenesis and growth of human
glioblastoma after treatment with
monoclonal antibody DC101 against the
vascular endothelial growth factor receptor-2 and
monoclonal antibody C225 against the
epidermal growth factor receptor. Nude mice bearing intracerebral
glioblastoma xenografts were treated intraperitoneally with DC101 and
C225 either alone or in combination. Histopathological analysis of solid
tumor volume, satellite
tumor number, microvessel density,
tumor cell proliferation, and apoptosis was performed. In the DC101-treated group, solid
tumor volume and microvessel density were reduced by 59.7 and 64%, respectively;
tumor cell proliferative activity was reduced by 53.2% and the apoptotic index (AI) was increased by 66.7%; satellite
tumor number was enhanced by 84.4%.
C225 alone reduced satellite
tumor number by 43.3%, but had no effect on solid
tumor volume, microvessel density,
tumor cell proliferation, and apoptosis.
C225 combined with DC101 not only reduced solid
tumor volume, microvessel density,
tumor cell proliferative activity, and increased AI, but also reduced satellite
tumor number. Inhibition of angiogenesis achieved by DC101 can cause increased
tumor cell invasiveness. In our studies this increased
tumor cell invasiveness was inhibited simultaneously by
C225, which provides a theoretical basis for treatment of
glioblastoma by the method of combining drugs with different pharmacological activity.